Streetbeat News

Products Services

PHIO

Phio Pharmaceuticals has announced the enrollment of the first US patient in a Phase 1B clinical trial for intratumoral PH-762 Anti-PD-1 therapy for the treatment of skin carcinomas. This marks a significant step in the company's clinical development program.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:33 pm

LILM

Lilium has entered into a partnership with Michelin for the development and serial production of tires for the Lilium Jet. The partnership aims to create custom, sustainable, and high-performance tires for the electric vertical take-off and landing (eVTOL) aircraft.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:33 pm

IKNA

Ikena Oncology has shared initial data from the ongoing dose escalation portion of its Phase 1 trial of IK-930. The data shows signs of clinical activity and tumor shrinkage in multiple patients with difficult-to-treat Epithelioid Hemangioendothelioma.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:31 pm

FCDI

IPSC

Century Therapeutics and Fujifilm Cellular Dynamics have announced a new worldwide license deal and expansion of existing licenses for the development and commercialization of cell therapies for the treatment of autoimmune and inflammatory diseases.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:23 pm

VVV

Valvoline has announced its expectation for FY24 adjusted EPS to be between $1.40-$1.65. The company also plans to add 140-170 stores to its network, with 55-70 of these coming from franchisees.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:19 pm

EVTV

Envirotech Vehicles has launched its first fully electric school bus, named the EVT Bumble Bee.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:43 am

ONCY

Oncolytics has updated its pancreatic cancer program for Pelareorep. The company, in collaboration with The Pancreatic Cancer Action Network (PanCAN), had initially planned to initiate a Phase 3 trial using the Precision Promise platform in H1 2024. However, Oncolytics now plans to conduct an adaptive Phase 3 program and manage it directly within its Clinical Group and a contract research organization, with the goal of enrolling the first patient in mid-2024.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:35 am

HCM

TAK

Hutchmed's partner Takeda has received FDA approval for Fruzaqla (Fruquintinib) for previously treated metastatic colorectal cancer patients. The approval was received under priority review over 20 days ahead of the scheduled Prescription Drug Users Fee.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:26 am

MSFT

QCOM

TMUS

The Humane AI Pin, an AI-powered device, is set to cost $699 with a $24 monthly subscription. The device operates on a Humane-branded version of T-Mobile US Inc.'s network and uses AI models from Microsoft Corp. and OpenAI. It is powered by a custom-designed processor for wearables from Qualcomm Inc. The AI Pin can draft messages, summarize emails, translate languages, identify food for nutritional data, and support Tidal music streaming.

Portfolio Pulse from Rounak Jain

November 09, 2023 | 11:21 am